Roivant Sciences Ltd. ROIV
4 trading plans running, 56 Form 144 notices for $557.0M
10-Q, 10-K and Form 144What ROIV's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Jun 25, 2024 to Oct 20, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Frank Torti, President and Vant Chair |
Adopted 10b5-1 plan | Aug 13, 2026 | 10-Q Nov 9, 2026 | ||
What the company wroteOn August 13, 2026, Dr. Frank Torti, President and Vant Chair of our subsidiary Roivant Sciences, Inc., entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale of up to 5,583,448 common shares held by Dr. Torti between November 12, 2026 and June 20, 2027. | |||||
| Eric Venker President and Immunovant CEO |
Adopted 10b5-1 plan | Jun 30, 2026 | 10-Q Aug 6, 2026 | ||
What the company wroteOn June 30, 2026, Eric Venker, President and Immunovant CEO of our subsidiary Roivant Sciences, Inc., entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale of up to 1,787,943 common shares held by Dr. Venker between October 20, 2026 and October 20, 2027. | |||||
| Meghan FitzGerald director |
Adopted 10b5-1 plan | Mar 30, 2026 | 10-K May 20, 2026 | ||
What the company wroteOn March 30, 2026, Meghan FitzGerald, a director of RSL, entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale between July 29, 2026 and July 1, 2027 of up to 30,000 common shares held by Ms. FitzGerald as well as up to 40% of the net number of common shares resulting from the RSU vesting event on September 10, 2026. | |||||
| Melissa Epperly director |
Adopted 10b5-1 plan | Mar 30, 2026 | 10-K May 20, 2026 | ||
What the company wroteOn March 30, 2026, Melissa Epperly, a director of RSL, entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale between July 29, 2026 and June 30, 2027 of up to 71,000 common shares held by Ms. Epperly as well as up to 40% of the net number of common shares resulting from the RSU vesting event on September 10, 2026. | |||||
| Frank Torti President and Vant Chair |
Adopted 10b5-1 plan | Nov 20, 2025 | 10-Q Feb 6, 2026 | ||
What the company wroteOn November 20, 2025, Frank Torti, President and Vant Chair of our subsidiary Roivant Sciences, Inc. entered into a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale of up to 3,000,000 common shares held by Dr. Torti between February 19, 2026 and June 30, 2026 | |||||
| Eric Venker President and Chief Operating Officer |
Adopted 10b5-1 plan | Mar 28, 2025 | 10-K May 29, 2025 | ||
| Eric Venker President, Chief Operating Officer |
Adopted 10b5-1 plan | Jun 25, 2024 | 10-Q Aug 9, 2024 | ||
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since Jun 28, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 13, 2026 | RICHARD PULIK Officer |
125,000 | $5.2M |
| Nov 13, 2026 | Pulik Richard Officer |
175,000 | $7.3M |
| Nov 12, 2026 | RICHARD PULIK Officer, Director |
175,000 | $7.3M |
| Nov 10, 2026 | Venker Eric Officer |
187,943 | $7.6M |
| Nov 10, 2026 | FRANK M TORTI Officer |
1,234,964 | $50.7M |
| Nov 10, 2026 | MATTHEW ADAM GLINE Officer, Director |
164,136 | $6.7M |
| Nov 10, 2026 | MAYUKH SUKHATME Officer, Director |
173,725 | $7.1M |
| Nov 10, 2026 | MAYUKH SUKHATME Officer, Director |
173,725 | $7.1M |
| Nov 10, 2026 | MATTHEW ADAM GLINE Officer, Director |
164,136 | $6.7M |
| Nov 10, 2026 | FRANK M TORTI Officer |
1,234,964 | $50.7M |
| Nov 10, 2026 | RICHARD PULIK Officer, Director |
125,000 | $5.2M |
| Nov 3, 2026 | Venker Eric Officer |
200,000 | $7.3M |
| Oct 28, 2026 | Venker Eric Officer |
200,000 | $7.3M |
| Oct 20, 2026 | Venker Eric Officer |
200,000 | $7.0M |
| Sep 30, 2026 | Venker Eric Officer |
200,000 | $7.3M |
| Sep 15, 2026 | MELISSA EPPERLY Director |
22,688 | $931K |
| Sep 15, 2026 | MEGHAN FITZGERALD Officer |
5,112 | $210K |
| Sep 8, 2026 | MEGHAN FITZGERALD Director |
20,000 | $699K |
| Aug 28, 2026 | Venker Eric Officer |
200,000 | $7.1M |
| Aug 21, 2026 | MAYUKH SUKHATME Officer, Director |
144,756 | $5.3M |
| Aug 20, 2026 | MAYUKH SUKHATME Officer, Director |
17,519 | $653K |
| Aug 19, 2026 | MAYUKH SUKHATME Officer, Director |
172,899 | $6.4M |
| Aug 18, 2026 | MAYUKH SUKHATME Officer, Director |
136,942 | $5.0M |
| Aug 17, 2026 | MAYUKH SUKHATME Officer, Director |
284,707 | $10.3M |
| Aug 14, 2026 | MAYUKH SUKHATME Officer, Director |
243,177 | $8.8M |
| Jul 27, 2026 | Venker Eric Officer |
200,000 | $7.0M |
| Jun 30, 2026 | MEGHAN FITZGERALD Director |
10,000 | $347K |
| Jun 30, 2026 | KEITH S MANCHESTER Director |
200,000 | $7.1M |
| Jun 29, 2026 | MELISSA EPPERLY Director |
17,750 | $605K |
| Jun 26, 2026 | MAYUKH SUKHATME Officer, Director |
500,000 | $17.0M |
| Jun 25, 2026 | MAYUKH SUKHATME Officer, Director |
500,000 | $17.1M |
| Jun 24, 2026 | Venker Eric Officer |
200,000 | $6.6M |
| May 22, 2026 | Venker Eric Officer |
200,000 | $6.1M |
| Apr 20, 2026 | Venker Eric Officer |
200,000 | $5.9M |
| Apr 16, 2026 | Gline Matthew Officer |
289,774 | $8.4M |
| Apr 16, 2026 | Gline Matthew Officer |
289,774 | $8.4M |
| Apr 8, 2026 | JENNIFER HUMES Officer |
13,538 | $384K |
| Mar 26, 2026 | MEGHAN FITZGERALD Director |
70,000 | $1.9M |
| Mar 17, 2026 | Venker Eric Officer |
200,000 | $5.6M |
| Mar 16, 2026 | MELISSA B EPPERLY Director |
41,861 | $1.2M |
| Feb 20, 2026 | FRANK TORTI Officer |
1,600,000 | $44.0M |
| Feb 19, 2026 | FRANK TORTI Officer |
1,400,000 | $38.5M |
| Feb 13, 2026 | Venker Eric Officer |
200,000 | $5.3M |
| Feb 9, 2026 | Sukhatme Mayukh Officer |
339,441 | $9.0M |
| Jan 12, 2026 | Venker Eric Officer |
200,000 | $4.4M |
| Dec 31, 2025 | Sukhatme Mayukh Officer |
1,018,995 | $22.1M |
| Dec 29, 2025 | Sukhatme Mayukh Officer |
311,873 | $6.8M |
| Dec 29, 2025 | ERIC VENKER Officer |
75,000 | $1.7M |
| Dec 29, 2025 | FRANK M TORTI Officer, Director |
64,891 | $1.5M |
| Dec 23, 2025 | RICHARD PULIK Officer |
260,000 | $5.8M |
| Dec 23, 2025 | RICHARD PULIK TRUST Officer |
146,731 | $3.3M |
| Dec 23, 2025 | ERIC VENKER Officer |
200,000 | $4.5M |
| Dec 17, 2025 | Sukhatme Mayukh Officer |
26,831 | $619K |
| Dec 15, 2025 | Gline Matthew Officer |
1,740,000 | $37.7M |
| Dec 15, 2025 | Gline Matthew Officer |
1,740,000 | $37.7M |
| Dec 9, 2025 | Venker Eric Officer |
200,000 | $4.2M |
Show the other 48 notices
From the Form 144 XML filed with the SEC, since Dec 9, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.